Sign In  |  Register  |  About Santa Clara  |  Contact Us

Santa Clara, CA
September 01, 2020 1:39pm
7-Day Forecast | Traffic

  • Search Hotels in Santa Clara

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

90.19 +0.43 (+0.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Peering Into Gilead Sciences's Recent Short Interest
Via Benzinga
This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Via Benzinga
Evaluating Gilead Sciences: Insights From 15 Financial Analysts
Via Benzinga
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
From Gilead Sciences, Inc.
Via Business Wire
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Will GILEAD SCIENCES INC breakout?
Technical Signals Point to a Possible Breakout for GILEAD SCIENCES INC. 
Via Chartmill
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact... 
Via Benzinga
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Via Benzinga
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
From Gilead Sciences, Inc.
Via Business Wire
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential... 
Via Benzinga
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
Via Benzinga
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
From Gilead Sciences, Inc.
Via Business Wire
Biotech Stocks Poised For Another Big Move In Q4
The healthcare sector can be a safe haven if volatility increases. 
Via Talk Markets
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
From Gilead Sciences, Inc.
Via Business Wire
News Is Noise
Via Talk Markets
Gilead Sciences Unusual Options Activity For September 20
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Via Benzinga
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
Goldman Sachs raises S&P 500's EPS forecast to $268 in 2025, driven by AI tech demand & semiconductor recovery. Margin expansion & macro growth fuel optimism for tech & healthcare sectors. 
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
From Gilead Sciences, Inc.
Via Business Wire
Top 4 Health Care Stocks That May Keep You Up At Night
Via Benzinga
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
Gilead Sciences has recalled one lot of its COVID-19 treatment, Veklury (remdesivir), due to glass particles found in vials. Gilead is notifying distributors to cease use and return the remaining... 
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
The Federal Reserve's recent 50bps rate cut could significantly boost biotech companies by lowering borrowing costs and improving access to capital. 
Via MarketBeat
Topics ETFs Economy
Exposures Economy Interest Rates
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
The company is still discussing the future for its Daiichi Sankyo-partnered ADC in metastatic breast cancer treatment. 
Via Investor's Business Daily
3 Dirt Cheap Stocks to Buy Right Now
Bargain hunters should love these great stocks. 
Via The Motley Fool
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
These two stocks have had their issues in recent years, but both look like reliable long-term bets. 
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SantaClara.com & California Media Partners, LLC. All rights reserved.